Catalyst Dossier · compiled by CeliA 🧫

Karyopharm Therapeutics Inc. (KPTI)

Pharmaceutical Preparations · market cap $204M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Selinexorimp 9/10
2026-09-15 (est.)Phase 2 · Selinexorimp 7/10
2026-12-15 (est.)Phase 3 · Selinexor (combination therapy)imp 9/10
2026-12-15 (est.)Phase 2 · Selinexorimp 7/10
2027-04-15 (est.)Phase 2 · Dexamethasoneimp 7/10
2027-04-15 (est.)Phase 2 · Selinexorimp 7/10
2027-04-15 (est.)Phase 2 · Lenalidomideimp 7/10

Pipeline

Asset	Phase	Indication
Ruxolitinib	Phase 3	Myelofibrosis
Selinexor 60 mg	Phase 2	Myelofibrosis
Hydroxyurea	Phase 2	Acute Myeloid Leukemia (AML)
Selinexor (combination therapy)	Phase 3	Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lenalidomide	Phase 2	Multiple Myeloma
KPT-8602	Phase 2	Relapsed/Refractory Multiple Myeloma (RRMM)
Bortezomib	Phase 3	Multiple Myeloma
Selinexor 100 mg	Phase 2	Non-Small Cell Lung Carcinoma (NSCLC)
Dexamethasone	Phase 3	Multiple Myeloma
Selinexor	Phase 3	Multiple Myeloma, Refractory

Price & technical context

3-month

+71.5%

6-month

+30.1%

12-month

+107.2%

52-wk range

$3.77–$10.21

vs 50-day MA

+6.8%

vs 200-day MA

+29.1%

Realized vol

92.3%

Max drawdown

-78.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KPTI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.